Literature DB >> 26811624

Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.

Tasuku Matsuoka1, Masakazu Yashiro1.   

Abstract

Pancreatic cancer is the fourth most common cause of cancer deaths worldwide. Although recent therapeutic developments for patients with pancreatic cancer have provided survival benefits, the outcomes for patients with pancreatic cancer remain unsatisfactory. Molecularly targeted cancer therapy has advanced in the past decade with the use of a number of pathways as candidates of therapeutic targets. This review summarizes the molecular features of this refractory disease while focusing on the recent clinical and experimental findings on pancreatic cancer. It also discusses the data supporting current standard clinical outcomes, and offers conclusions that may improve the management of pancreatic cancer in the future.

Entities:  

Keywords:  Cancer stem cell; Microenvironment; Pancreatic cancer; Targeted therapy; Tyrosine kinase inhibitors

Mesh：

Substances：

Year:  2016        PMID： 26811624      PMCID： PMC4716076          DOI： 10.3748/wjg.v22.i2.776

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  102 in total

Review 1.  Treatment of metastatic pancreatic adenocarcinoma: a review.

Authors:  Ramya Thota; James M Pauff; Jordan D Berlin
Journal:  Oncology (Williston Park)       Date:  2014-01       Impact factor: 2.990

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.

Authors:  Lei Li; Zhaoshen Li; Xiangyu Kong; Dacheng Xie; Zhiliang Jia; Weihua Jiang; Jiujie Cui; Yiqi Du; Daoyan Wei; Suyun Huang; Keping Xie
Journal:  Gastroenterology       Date:  2014-05-20       Impact factor: 22.682

4.  EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy.

Authors:  Walter G Park; Brian M Yan; Devin Schellenberg; Jeff Kim; Daniel T Chang; Albert Koong; Cheryl Patalano; Jacques Van Dam
Journal:  Gastrointest Endosc       Date:  2010-03       Impact factor: 9.427

5.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Authors:  M Schutte; R H Hruban; J Geradts; R Maynard; W Hilgers; S K Rabindran; C A Moskaluk; S A Hahn; I Schwarte-Waldhoff; W Schmiegel; S B Baylin; S E Kern; J G Herman
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

Review 6.  Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy.

Authors:  Thomas Helleday; Helen E Bryant; Niklas Schultz
Journal:  Cell Cycle       Date:  2005-09-12       Impact factor: 4.534

7.  Sonic hedgehog promotes desmoplasia in pancreatic cancer.

Authors:  Jennifer M Bailey; Benjamin J Swanson; Tomofumi Hamada; John P Eggers; Pankaj K Singh; Thomas Caffery; Michel M Ouellette; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

8.  Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors.

Authors:  Christine A Iacobuzio-Donahue; Jason Song; Giovanni Parmiagiani; Charles J Yeo; Ralph H Hruban; Scott E Kern
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

9.  Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.

Authors:  Tiansuo Zhao; He Ren; Li Jia; Jing Chen; Wen Xin; Fan Yan; Jing Li; Xiuchao Wang; Song Gao; Dong Qian; Chongbiao Huang; Jihui Hao
Journal:  Oncotarget       Date:  2015-02-10

10.  IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer.

Authors:  Toshiki Hirakawa; Masakazu Yashiro; Akihiro Murata; Keiichiro Hirata; Kenjiro Kimura; Ryosuke Amano; Nobuya Yamada; Bunzo Nakata; Kosei Hirakawa
Journal:  BMC Cancer       Date:  2013-08-21       Impact factor: 4.430
View more
  16 in total

1.  Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer.

Authors:  Xifeng Xu; Qiong Wu; Zhen Wang; Song Zheng; Ke Ge; Changku Jia
Journal:  Clin Exp Med       Date:  2018-11-29       Impact factor: 3.984

Review 2.  Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival.

Authors:  Mark B Ulanja; Alastair E Moody; Bryce D Beutler; Daniel Antwi-Amoabeng; Ganiyu A Rahman; Olatunji B Alese
Journal:  Oncotarget       Date:  2022-06-15

3.  In vitro comparative studies of resveratrol and triacetylresveratrol on cell proliferation, apoptosis, and STAT3 and NFκB signaling in pancreatic cancer cells.

Authors:  JingJing Duan; Wen Yue; JianYu E; Jyoti Malhotra; Shou-En Lu; Jun Gu; Feng Xu; Xiang-Lin Tan
Journal:  Sci Rep       Date:  2016-08-19       Impact factor: 4.379

Review 4.  Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer.

Authors:  Jiangang Zhao; Jiahui Li; Hans A Schlößer; Felix Popp; Marie Christine Popp; Hakan Alakus; Karl-Walter Jauch; Christiane J Bruns; Yue Zhao
Journal:  Stem Cells Int       Date:  2017-08-06       Impact factor: 5.443

Review 5.  Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options.

Authors:  Chandra Diwakarla; Katherine Hannan; Nadine Hein; Desmond Yip
Journal:  World J Gastroenterol       Date:  2017-04-07       Impact factor: 5.742

Review 6.  Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma.

Authors:  Matthew Loft; Belinda Lee; Jeanne Tie; Peter Gibbs
Journal:  J Pers Med       Date:  2019-07-18

7.  Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition.

Authors:  Oliver A Kent; Maria-Jose Sandi; Robert Rottapel
Journal:  Small GTPases       Date:  2017-07-11

8.  Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies.

Authors:  Federica Eduati; Patricia Jaaks; Jessica Wappler; Thorsten Cramer; Christoph A Merten; Mathew J Garnett; Julio Saez-Rodriguez
Journal:  Mol Syst Biol       Date:  2020-02       Impact factor: 11.429

9.  Berbamine Enhances the Efficacy of Gefitinib by Suppressing STAT3 Signaling in Pancreatic Cancer Cells.

Authors:  Bingren Hu; Huajie Cai; Shouzhang Yang; Jinfu Tu; Xiaming Huang; Gang Chen
Journal:  Onco Targets Ther       Date:  2019-12-24       Impact factor: 4.147

10.  Quantification of fluorophore distribution and therapeutic response in matched in vivo and ex vivo pancreatic cancer model systems.

Authors:  Allison Solanki; Diana King; Guillaume Thibault; Lei Wang; Summer L Gibbs
Journal:  PLoS One       Date:  2020-02-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.